eMedicine Specialties > Dermatology > Fungal Infections

Tinea Corporis: Treatment & Medication

Author: Mary Elizabeth Rushing Lott, MD, Senior Resident, Department of Pediatrics, Miami Children's Hospital
Coauthor(s): Gwendolyn Zember, MD, Consulting Staff, Department of Internal Medicine, University Hospital; Jack L Lesher Jr, MD, Chief, Professor, Department of Internal Medicine, Section of Dermatology, Medical College of Georgia
Contributor Information and Disclosures

Updated: Jun 5, 2008

Treatment

Medical Care

Topical therapy is recommended for a localized infection because dermatophytes rarely invade living tissues. Topical therapy should be applied to the lesion and at least 2 cm beyond this area once or twice a day for at least 2 weeks, depending on which agent is used. Topical azoles and allylamines show high rates of clinical efficacy. These agents inhibit the synthesis of ergosterol, a major fungal cell membrane sterol. 

  • The topical azoles (eg, econazole, ketoconazole, clotrimazole, miconazole, oxiconazole, sulconazole, sertaconazole) inhibit the enzyme lanosterol 14-alpha-demethylase, a cytochrome P-450–dependent enzyme that converts lanosterol to ergosterol. Inhibition of this enzyme results in unstable fungal cell membranes and causes membrane leakage. The weakened dermatophyte is unable to reproduce and is slowly killed by fungistatic action. Sertaconazole nitrate is one of the newest topical azoles. It has fungicidal and anti-inflammatory abilities and is used as a broad-spectrum agent. It may have a reservoir effect and therefore is a good choice for noncompliant patients. Lastly, Liebel et al published in vitro data in 2006, reporting this drug has anti-itch properties.8
  • Allylamines (eg, naftifine, terbinafine) and the related benzylamine butenafine inhibit squalene epoxidase, which converts squalene to ergosterol. Inhibition of this enzyme causes squalene, a substance toxic to fungal cells, to accumulate intracellularly and leads to rapid cell death. Allylamines bind effectively to the stratum corneum because of their lipophilic nature. They also penetrate deeply into hair follicles.9
  • Ciclopirox olamine is a topical fungicidal agent. It causes membrane instability by accumulating inside fungal cells and interfering with amino acid transport across the fungal cell membrane.
  • A low-to-medium potency topical corticosteroid can be added to the topical antifungal regimen to relieve symptoms. The steroid can provide rapid relief from the inflammatory component of the infection, but the steroid should only be applied for the first few days of treatment. Prolonged use of steroids can lead to persistent and recurrent infections, longer duration of treatment regimens, and adverse effects of skin atrophy, striae, and telangiectasias.

Systemic therapy may be indicated for tinea corporis that includes extensive skin infection, immunosuppression, resistance to topical antifungal therapy, and comorbidities of tinea capitis or tinea unguium. Use of oral agents requires attention to potential drug interactions and monitoring for adverse effects.

  • The mechanism of action or oral micronized griseofulvin against dermatophytes is disruption of the microtubule mitotic spindle formation in metaphase, causing arrest of fungal cell mitosis. A dose of 10 mg/kg/d for 4 weeks is effective. In addition, griseofulvin induces the cytochrome P-450 enzyme system and can increase the metabolism of CYP-450–dependent drugs. It is the systemic drug of choice for tinea corporis infections in children.
  • Systemic azoles (eg, fluconazole, itraconazole, ketoconazole) function similar to the topical agents, causing cell membrane destruction.9
    • Oral ketoconazole at 3-4 mg/kg/d may be given. However, this agent carries an associated risk of hepatitis in less than 1 in 10,000 cases and now is seldom used orally for dermatophyte infections.
    • Fluconazole at 50-100 mg/d or 150 mg once weekly for 2-4 weeks is used with good results.
    • Oral itraconazole in doses of 100 mg/d for 2 weeks shows high efficacy. With an increased dose of 200 mg/d, the treatment duration can be reduced to 1 week. However, the cytochrome P-450 activity of itraconazole allows for potential interactions with other commonly prescribed drugs.
    • Based on E-test for susceptibility of T rubrum, voriconazole was the most active and fluconazole was the least active of the azole drugs.10
  • Oral terbinafine may be used at a dosage of 250 mg/d for 2 weeks; the potential exists for cytochrome P-450, specifically CYP-2D6, drug interactions with this agent.
  • Systemic therapy is needed when the infection involves hair follicles, such as Majocchi granuloma. In this case, topical therapy may serve as adjunct treatment with the oral medication. 
  • The preferred treatment for tinea imbricata is griseofulvin or terbinafine, although some resistance has developed to oral griseofulvin.11

Surgical Care

Surgical treatment is usually not indicated except for drainage of superficial vesicles, bullae, pustules, or deep abscesses.

Medication

The goals of pharmacotherapy are to reduce morbidity and to prevent complications. Topical antifungal agents are effective for treating most cases of tinea corporis. Systemic therapy may be indicated for tinea corporis that is extensive, involves immunocompromised patients, or is refractory to topical therapy. For severe infections, systemic therapy can be combined with topical antifungal treatments.

Topical allylamines


Naftifine 1% cream or gel (Naftin)

Broad-spectrum antifungal agent that appears to interfere with sterol biosynthesis by inhibiting the enzyme squalene 2,3-epoxidase. This inhibition results in decreased amounts of sterols, causing cell death. If no clinical improvement occurs after 4 wk, reevaluate patient.

Adult

Cream or gel: Gently massage sufficient quantity into affected area and surrounding skin qd for 2-4 wk

Pediatric

Administer as in adults

Pregnancy

B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals

Precautions

Discontinue use if sensitivity or chemical irritation occurs; for external use only; avoid contact with eyes


Terbinafine 1% cream (Lamisil)

Fungicidal activity; synthetic allylamine derivative that inhibits squalene epoxidase, a key enzyme in sterol biosynthesis of fungi, resulting in deficiency in ergosterol that causes fungal cell death. Use until symptoms significantly improve.

Adult

Apply to affected area qd for 1-4 wk

Pediatric

<12 years: Not established
>12 years: Administer as in adults

Pregnancy

B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals

Precautions

Discontinue use if chemical irritation develops

Topical pyridones


Ciclopirox olamine 1% cream (Loprox)

Interferes with synthesis of DNA, RNA, and protein by inhibiting transport of essential elements in fungal cells.

Adult

Massage into affected areas bid for 3-4 wk; reevaluate diagnosis if no improvement after 4 wk

Pediatric

<10 years: Not established
>10 years: Administer as in adults

Pregnancy

B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals

Precautions

Avoid contact with eyes and other internal routes; discontinue if sensitivity or irritation occurs

Topical benzylamines


Butenafine 1% cream (Mentax)

Inhibits squalene epoxidation, which, in turn, causes blockage of ergosterol biosynthesis (an essential component of fungal cell membranes), causing fungal cell growth to arrest.

Adult

Apply qd to affected and surrounding area for 2 wk

Pediatric

<12 years: Not established
>12 years: Administer as in adults

Pregnancy

B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals

Precautions

Use topically (not in eyes, vagina, or other internal routes)

Systemic azoles


Fluconazole (Diflucan)

Synthetic oral antifungal (broad-spectrum bistriazole) that selectively inhibits fungal cytochrome P-450 and sterol C-14 alpha-demethylation, which prevents conversion of lanosterol to ergosterol, thereby disrupting cellular membranes. Has little affinity for mammalian cytochromes, which is believed to explain its low toxicity. Available as tab for oral administration, as powder for oral susp, and as a sterile solution for IV use. Has fewer adverse effects and better tissue distribution than older systemic imidazoles.

Adult

150 mg/wk PO for 2-4 wk

Pediatric

Not established

Levels may increase with hydrochlorothiazides; levels may decrease with long-term coadministration of rifampin; may increase concentrations of theophylline, phenytoin, tolbutamide, cyclosporine, glyburide, and glipizide; effects of anticoagulants may increase with coadministration; increases in cyclosporine concentrations may occur when administered concurrently; cisapride administration may cause torsade de pointes

Documented hypersensitivity; coadministration with terfenadine in patients receiving fluconazole at multiple doses of >400 mg

Pregnancy

C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus

Precautions

Adjust dose for renal insufficiency; also associated with anaphylaxis and exfoliative skin disorders (closely monitor if rashes develop and discontinue drug if lesions progress); may cause clinical hepatitis, cholestasis, and fulminant hepatic failure (including death) when taken with underlying medical conditions (eg, AIDS, malignancy) or while taking multiple concomitant medications; not recommended for breastfeeding mothers


Itraconazole (Sporanox)

Fungistatic activity; synthetic triazole antifungal agent that inhibits fungal cell growth by inhibiting the cytochrome P-450–dependent synthesis of ergosterol, a vital component of fungal cell membranes.

Adult

100 mg/d PO for 2 wk or 200 mg/d PO for 1 wk; not to exceed 400 mg/d; increase in 100-mg increments if no improvement (administer >200 mg/d in divided doses)

Pediatric

Not established
Suggested for children 3-16 years: 100 mg/d PO for 1 wk

Antacids may reduce absorption; edema may occur with coadministration of calcium channel blockers (eg, amlodipine, nifedipine); hypoglycemia may occur with sulfonylureas; may increase tacrolimus and cyclosporine plasma concentrations when high doses are used; rhabdomyolysis may occur with coadministration of HMG-CoA reductase inhibitors (ie, lovastatin, simvastatin); coadministration with cisapride can cause cardiac rhythm abnormalities and death; may increase digoxin levels; coadministration may increase plasma levels of midazolam or triazolam; phenytoin and rifampin may reduce levels (phenytoin metabolism may be altered)

Pregnancy

C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus

Precautions

Caution in hepatic insufficiencies (rare cases of reversible idiosyncratic hepatitis reported); monitor hepatic enzyme test values in preexisting hepatic function abnormalities


Ketoconazole (Nizoral)

Inhibits synthesis of ergosterol (main sterol of fungal cell membranes), causing cellular components to leak; results in cell death.

Adult

200-400 mg PO qd

Pediatric

3.3-6.6 m/kg PO qd for 4 wk, not to exceed 400 mg/dose

Isoniazid may decrease bioavailability; coadministration decreases effects of either rifampin or ketoconazole; may increase effect of anticoagulants; may increase toxicity of corticosteroids and cyclosporine (cyclosporine dosage can be adjusted); may decrease theophylline levels; decreases metabolism of repaglinide, thus increasing serum levels and effects

Documented hypersensitivity; fungal meningitis

Pregnancy

C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus

Precautions

Hepatotoxicity may occur; may reversibly decrease corticosteroid serum levels (adverse effects avoided with dose of 200-400 mg/d); administer antacids, anticholinergics, or H2-blockers at least 2 h after taking ketoconazole

Systemic allylamines


Terbinafine (Lamisil, Daskil)

Fungicidal activity; synthetic allylamine derivative that inhibits squalene epoxidase, a key enzyme in sterol biosynthesis of fungi, resulting in a deficiency in ergosterol that causes fungal cell death. Use until symptoms significantly improve.

Adult

250 mg/d PO for 1-2 wk

Pediatric

Terbinafine tab; treatment duration similar to that in adults
10-20 kg: 62.5 mg/d PO
20-40 kg: 125 mg/d PO
>40 kg: 250 mg/d PO

May decrease cyclosporine effects; toxicity may increase with rifampin and cimetidine

Pregnancy

B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals

Precautions

Discontinue use if acute generalized exanthematous pustulosis, angioedema, desquamation, erythema multiforme, erythroderma, bullous pemphigoid, lupus erythematosus, pustular psoriasis, lichenoid eruption, Stevens-Johnson syndrome, toxic epidermal necrolysis, urticaria, or alopecia erupts or if hepatobiliary dysfunction, neutropenia, or changes in ocular lens or retina develops; transient decreases in absolute lymphocyte count have been observed in controlled clinical trials

Other systemic antifungals


Griseofulvin (Fulvicin)

Fungistatic activity; fungal cell division is impaired by interfering with microtubule. Binds to keratin precursor cells. Keratin is gradually replaced by noninfected tissue, which is highly resistant to fungal invasions.

Adult

500 mg microsize (330-375 mg ultramicrosize) PO in single or divided daily doses

Pediatric

20 mg microsize/kg/d (5 mg/lb/d) PO or 7.3 mg ultramicrosize/kg/d (3.3 mg/lb/d) PO

May decrease hypoprothrombinemic activity of warfarin; contraceptives may lose their effectiveness; may reduce effects of cyclosporine; may decrease serum salicylate concentrations; barbiturates may decrease serum levels

Pregnancy

C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus

Precautions

On prolonged therapy, observe patients closely; monitor renal, hepatic, and hematopoietic function regularly; lupuslike syndromes or exacerbation of lupus erythematosus may occur; photosensitivity may also occur (patients should take protective measures against exposure to UV light or sunlight)

Topical azoles


Clotrimazole 1% cream (Mycelex, Lotrimin)

Nonabsorbable imidazole. Broad-spectrum synthetic antifungal agent that inhibits growth of fungus by altering cell membrane permeability, which causes fungal cell death.
Therapy is directed at the underlying condition, with the goal of minimizing symptoms and preventing complications.

Adult

Gently massage into affected and surrounding skin areas bid for 2-6 wk

Pediatric

Apply as in adults

Pregnancy

C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus

Precautions

Not for treatment of systemic fungal infections; avoid contact with the eyes; if irritation or sensitivity develops, discontinue use and institute appropriate therapy


Ketoconazole 2% cream (Nizoral)

Imidazole, broad-spectrum antifungal agent indicated for topical treatment of tinea corporis. Inhibits synthesis of ergosterol (main sterol of fungal cell membranes), causing cellular components to leak; result is cell death.

Adult

Rub gently into affected area qd or bid for 2-4 wk

Pediatric

Apply as in adults

Documented hypersensitivity; fungal meningitis

Pregnancy

C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus

Precautions

If sensitivity or irritation develops, discontinue use; for external use only; avoid contact with eyes


Miconazole 2% cream or lotion (Monistat)

Damages fungal cell-wall membrane by inhibiting biosynthesis of ergosterol. Membrane permeability is increased, causing nutrients to leak and resulting in fungal cell death. Lotion is preferred in intertriginous areas. If cream is used, apply sparingly to avoid maceration effects.

Adult

Cream and lotion: Cover affected areas bid for 2-6 wk
Powder: Spray or sprinkle liberally over affected area bid

Pediatric

Apply as in adults

Pregnancy

C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus

Precautions

If sensitivity or irritation develops, discontinue use; for external use only; avoid contact with eyes


Oxiconazole 1% cream (Oxistat)

Damages fungal cell wall membrane by inhibiting biosynthesis of ergosterol. Membrane permeability is increased, causing nutrients to leak, resulting in fungal cell death.

Adult

Apply to affected area qid

Pediatric

Administer as in adults

Pregnancy

C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus

Precautions

If sensitivity or chemical irritation occurs, discontinue use; external use only; avoid contact with the eyes


Sertaconazole 2% cream (Ertaczo)

Topical imidazole antifungal active against T rubrum, T mentagrophytes, and Epidermophyton floccosum.

Adult

Apply topically bid for 2-4 wk

Pediatric

<12 years: Not established
>12 years: Administer as in adults

Pregnancy

C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus

Precautions

For topical use only; may cause dermatitis, dry skin, burning sensation, pruritus, hyperpigmentation, desquamation, or skin tenderness


Sulconazole 1% cream or solution (Exelderm)

Broad-spectrum antifungal agent that inhibits synthesis of ergosterol, causing cellular components to leak and resulting in fungal cell death.

Adult

Apply topically to affected area qd for 2-4 wk

Pediatric

<12 years: Not established
>12 years: Administer as in adults

Pregnancy

C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus

Precautions

If sensitivity or chemical irritation occurs, discontinue use; use only externally; avoid contact with the eyes

More on Tinea Corporis

Overview: Tinea Corporis
Differential Diagnoses & Workup: Tinea Corporis
Treatment & Medication: Tinea Corporis
Follow-up: Tinea Corporis
Multimedia: Tinea Corporis
References

References

  1. Adams BB. Tinea corporis gladiatorum. J Am Acad Dermatol. Aug 2002;47(2):286-90. [Medline].

  2. Sun PL, Ho HT. Concentric rings: an unusual presentation of tinea corporis caused by Microsporum gypseum. Mycoses. Mar 2006;49(2):150-1. [Medline].

  3. Sánchez-Castellanos ME, Mayorga-Rodríguez JA, Sandoval-Tress C, Hernández-Torres M. Tinea incognito due to Trichophyton mentagrophytes. Mycoses. Jan 2007;50(1):85-7. [Medline].

  4. Kim HS, Cho BK, Oh ST. A case of tinea corporis purpurica. Mycoses. Jul 2007;50(4):314-6. [Medline].

  5. Shiraki Y, Hiruma M, Matsuba Y, Kano R, Makimura K, Ikeda S, et al. A case of tinea corporis caused by Arthroderma benhamiae (teleomorph of Tinea mentagrophytes) in a pet shop employee. J Am Acad Dermatol. Jul 2006;55(1):153-4. [Medline].

  6. Placzek M, van den Heuvel ME, Flaig MJ, Korting HC. Perniosis-like tinea corporis caused by Trichophyton verrucosum in cold-exposed individuals. Mycoses. Nov 2006;49(6):476-9. [Medline].

  7. Seyfarth F, Ziemer M, Gräser Y, Elsner P, Hipler UC. Widespread tinea corporis caused by Trichophyton rubrum with non-typical cultural characteristics--diagnosis via PCR. Mycoses. 2007;50 Suppl 2:26-30. [Medline].

  8. Liebel F, Lyte P, Garay M, Babad J, Southall MD. Anti-inflammatory and anti-itch activity of sertaconazole nitrate. Arch Dermatol Res. Sep 2006;298(4):191-9. [Medline].

  9. Leyden J. Pharmacokinetics and pharmacology of terbinafine and itraconazole. J Am Acad Dermatol. May 1998;38(5 Pt 3):S42-7. [Medline].

  10. da Silva Barros ME, de Assis Santos D, Soares Hamdan J. Antifungal susceptibility testing of Trichophyton rubrum by E-test. Arch Dermatol Res. May 2007;299(2):107-9. [Medline].

  11. Wingfield AB, Fernandez-Obregon AC, Wignall FS, Greer DL. Treatment of tinea imbricata: a randomized clinical trial using griseofulvin, terbinafine, itraconazole and fluconazole. Br J Dermatol. Jan 2004;150(1):119-26. [Medline].

  12. Aly R. Ecology and epidemiology of dermatophyte infections. J Am Acad Dermatol. Sep 1994;31(3 Pt 2):S21-5. [Medline].

  13. Dahl MV. Dermatophytosis and the immune response. J Am Acad Dermatol. Sep 1994;31(3 Pt 2):S34-41. [Medline].

  14. Del Rosso JQ, Draelos ZD, Jorizzo JL, Joseph WS, Ribotsky BM, Rich P. Modern methods to treat superficial fungal disease. Cutis. Feb 2007;79(2 Suppl):6-29. [Medline].

  15. Drake LA, Dinehart SM, Farmer ER, Goltz RW, Graham GF, Hardinsky MK, et al. Guidelines of care for superficial mycotic infections of the skin: tinea corporis, tinea cruris, tinea faciei, tinea manuum, and tinea pedis. Guidelines/Outcomes Committee. American Academy of Dermatology. J Am Acad Dermatol. Feb 1996;34(2 Pt 1):282-6. [Medline].

  16. Foster KW, Ghannoum MA, Elewski BE. Epidemiologic surveillance of cutaneous fungal infection in the United States from 1999 to 2002. J Am Acad Dermatol. May 2004;50(5):748-52. [Medline].

  17. Gupta AK, Einarson TR, Summerbell RC, Shear NH. An overview of topical antifungal therapy in dermatomycoses. A North American perspective. Drugs. May 1998;55(5):645-74. [Medline].

  18. Jones HE. Immune response and host resistance of humans to dermatophyte infection. J Am Acad Dermatol. May 1993;28(5 Pt 1):S12-S18. [Medline].

  19. Lesher JL. Therapeutic agents for dermatologic fungal diseases. In: Elewski BE, ed. Cutaneous Fungal Infections. Malden: Blackwell Science; 1998:321-46.

  20. Lesher JL Jr. Oral therapy of common superficial fungal infections of the skin. J Am Acad Dermatol. Jun 1999;40(6 Pt 2):S31-4. [Medline].

  21. Macura AB. Dermatophyte infections. Int J Dermatol. May 1993;32(5):313-23. [Medline].

  22. Piérard GE, Arrese JE, Piérard-Franchimont C. Treatment and prophylaxis of tinea infections. Drugs. Aug 1996;52(2):209-24. [Medline].

  23. Rezabek GH, Friedman AD. Superficial fungal infections of the skin. Diagnosis and current treatment recommendations. Drugs. May 1992;43(5):674-82. [Medline].

  24. Theos A. Diagnosis and management of superficial cutaneous fungal infections in children. Pediatr Ann. Jan 2007;36(1):46-54. [Medline].

  25. Weinstein A, Berman B. Topical treatment of common superficial tinea infections. Am Fam Physician. May 15 2002;65(10):2095-102. [Medline].

  26. Ziemer M, Seyfarth F, Elsner P, Hipler UC. Atypical manifestations of tinea corporis. Mycoses. 2007;50 Suppl 2:31-5. [Medline].

Further Reading

Keywords

ringworm, dermatophyte infection, Trichophyton species, Microsporum species, Epidermophyton species, Trichophyton rubrum, T rubrum, Microsporum canis, M canis, Trichophyton mentagrophytes, T mentagrophytes, Trichophyton tonsurans, T tonsurans, Trichophyton concentricum, T concentricum, Majocchi granuloma, Majocchi's granuloma, tinea imbricata, tinea capitis

Contributor Information and Disclosures

Author

Mary Elizabeth Rushing Lott, MD, Senior Resident, Department of Pediatrics, Miami Children's Hospital
Mary Elizabeth Rushing Lott, MD is a member of the following medical societies: Alpha Omega Alpha, American Medical Association, and American Medical Student Association/Foundation
Disclosure: Nothing to disclose.

Coauthor(s)

Gwendolyn Zember, MD, Consulting Staff, Department of Internal Medicine, University Hospital
Disclosure: Nothing to disclose.

Jack L Lesher Jr, MD, Chief, Professor, Department of Internal Medicine, Section of Dermatology, Medical College of Georgia
Jack L Lesher Jr, MD is a member of the following medical societies: American Academy of Dermatology, American Dermatological Association, American Medical Association, American Society for Dermatologic Surgery, Medical Association of Georgia, Society for Investigative Dermatology, and Southern Medical Association
Disclosure: Nothing to disclose.

Medical Editor

Janet Fairley, MD, Professor and Head, Department of Dermatology, University of Iowa
Janet Fairley, MD is a member of the following medical societies: American Academy of Dermatology, American Dermatological Association, American Federation for Medical Research, and Society for Investigative Dermatology
Disclosure: Nothing to disclose.

Pharmacy Editor

Richard P Vinson, MD, Assistant Clinical Professor, Department of Dermatology, Texas Tech University School of Medicine; Consulting Staff, Mountain View Dermatology, PA
Richard P Vinson, MD is a member of the following medical societies: American Academy of Dermatology, Association of Military Dermatologists, Texas Dermatological Society, and Texas Medical Association
Disclosure: Nothing to disclose.

Managing Editor

Rosalie Elenitsas, MD, Associate Professor of Dermatology, University of Pennsylvania School of Medicine; Director, Penn Cutaneous Pathology Services, Department of Dermatology, University of Pennsylvania Health System
Rosalie Elenitsas, MD is a member of the following medical societies: American Society of Dermatopathology
Disclosure: Nothing to disclose.

CME Editor

Joel M Gelfand, MD, MSCE, Medical Director, Clinical Studies Unit, Assistant Professor, Department of Dermatology, Associate Scholar, Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania
Joel M Gelfand, MD, MSCE is a member of the following medical societies: Society for Investigative Dermatology
Disclosure: AMGEN Consulting fee Consulting; AMGEN Grant/research funds None; Genentech Consulting fee Consulting; Centocor Consulting fee Consulting; Centocor Grant/research funds None; Covance Consulting fee Consulting; Shire  Consulting

Chief Editor

Dirk M Elston, MD, Director, Department of Dermatology, Geisinger Medical Center
Dirk M Elston, MD is a member of the following medical societies: American Academy of Dermatology
Disclosure: Nothing to disclose.

 
 
HONcode

We subscribe to the
HONcode principles of the
Health On the Net Foundation

All material on this website is protected by copyright, Copyright© 1994- by Medscape.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.